OAC
VTGN icon

OMERS Administration Corp’s VistaGen Therapeutics VTGN Stock Holding History

OMERS Administration Corp’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-103,400
Closed -$68.4K – 1178
2025
Q4 		$68.4K Buy
+103,400
New +$374K ﹤0.01% 992

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OMERS Administration Corp's VTGN Position: Q1 2026 in Review

OMERS Administration Corp sold out of VistaGen Therapeutics (VTGN) in Q1 2026, closing a stake of 103,400 shares — an estimated $68.4K sold.

OMERS Administration Corp first reported a position in VTGN in Q4 2025 and held it in 1 quarter. The position peaked at $68.4K in Q4 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • OMERS Administration Corp reported no remaining VistaGen Therapeutics position as of Q1 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 103,400 VistaGen Therapeutics shares in Q1 2026, an estimated $68.4K.
  • OMERS Administration Corp first reported a position in VistaGen Therapeutics in Q4 2025 and held it in 1 quarter.
  • OMERS Administration Corp's VistaGen Therapeutics position peaked at $68.4K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.